References
- Collaborative meta‐analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71–86
- Hankey G. J., Eikelboom J. W. Aspirin resistance. Lancet 2006; 367: 606–17
- Maree A. O., Fitzgerald D. J. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 2007; 115: 2196–207
- Snoep J. D., Hovens M. M., Eikenboom J. C., van der Bom J. G., Huisman M. V. Association of laboratory‐defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta‐analysis. Arch Intern Med 2007; 167: 1593–9
- Pettersen A. A., Seljeflot I., Abdelnoor M., Arnesen H. Unstable angina, stroke, myocardial infarction and death in aspirin non‐responders. A prospective, randomized trial. The ASCET (ASpirin non‐responsiveness and Clopidogrel Endpoint Trial) design. Scand Cardiovasc J 2004; 38: 353–6
- Meen Ø., Brosstad F., Khiabani H., Gjertsen E., Lauritsen M. E., Pedersen T. M., et al. No case of COX‐1 related aspirin resistance found in 289 patients with symptoms of stable CHD remitted for coronary angiography. Scand J Clin Lab Invest 2007; 67: 000–0
- Patrono C., Ciabattoni G., Pinca E., Pugliese F., Castrucci G., De S. A., et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980; 17: 317–27
- FitzGerald G. A., Pedersen A. K., Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 1983; 67: 1174–7
- Patrono C., Rocca B. Drug insight: aspirin resistance – fact or fashion?. Nat Clin Pract Cardiovasc Med 2007; 4: 42–50
- Perneby C., Wallen N. H., Rooney C., Fitzgerald D., Hjemdahl P. Dose‐ and time‐dependent antiplatelet effects of aspirin. Thromb Haemost 2006; 95: 652–8
- Tantry U. S., Bliden K. P., Gurbel P. A. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005; 46: 1705–9
- Schwartz K. A., Schwartz D. E., Ghosheh K., Reeves M. J., Barber K., DeFranco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005; 95: 973–5
- Cotter G., Shemesh E., Zehavi M., Dinur I., Rudnick A., Milo O., et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin?. Am Heart J 2004; 147: 293–300
- Valles J., Santos M. T., Fuset M. P., Moscardo A., Ruano M., Perez F., et al. Partial inhibition of platelet thromboxane A2 synthesis by aspirin is associated with myonecrosis in patients with ST‐segment elevation myocardial infarction. Am J Cardiol 2007; 99: 19–25
- Gurbel P. A., Bliden K. P., DiChiara J., Newcomer J., Weng W., Neerchal N. K., et al. Evaluation of dose‐related effects of aspirin on platelet function: results from the Aspirin‐Induced Platelet Effect (ASPECT) study. Circulation 2007; 115: 3156–64
- Poulsen T. S., Kristensen S. R., Korsholm L., Haghfelt T., Jorgensen B., Licht P. B., et al. Variation and importance of aspirin resistance in patients with known cardiovascular disease. Thromb Res 2007; 120: 477–84
- Lordkipanidze M., Pharand C., Schampaert E., Turgeon J., Palisaitis D. A., Diodati J. G. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28: 1702–8